title: Inhaled nitric oxide: are the safety issues being addressed?
abstract: Interest in the therapeutic uses of Nitric Oxide (NO) has gathered pace over the last decade. It is no exaggeration for the UK Guidelines on the Use of Inhaled Nitric Oxide (Cuthbertson et al. 1997) to say that 'the use of inhaled nitric oxide in the UK has become commonplace'. The index of the third edition (1990) of TE Oh's notable Intensive Care Manual carries no reference to it. Yet, from its origins in obscure research, the discovery of NO has promised the development of therapies which might include the revolutionary transformation of approaches to the treatment of septic shock. It also holds promise in the treatment of acute respiratory distress syndrome (ARDS). It is in this context that this discussion will seek to raise fundamental questions about the health and safety aspects of this substance.
authors: Edge Hill University College, Fazakerley Hospital, Liverpool, UK. Jonesch@sohs.ehche.ac.uk
authors: C
authors: C
authors: Jones
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D001993:Bronchodilator Agents / Q000009:adverse effects*; D002648:Child; D003422:Critical Care; D016166:Free Radical Scavengers / Q000009:adverse effects*; D006801:Humans; D008452:Maximum Allowable Concentration; D009569:Nitric Oxide / Q000009:adverse effects*; D016273:Occupational Exposure / Q000009:adverse effects*; D010564:Personnel, Hospital; D012128:Respiratory Distress Syndrome / Q000188:drug therapy*; D012772:Shock, Septic / Q000188:drug therapy*; D020711:Threshold Limit Values; D014665:Vasodilator Agents / Q000009:adverse effects*
chemical_list: D001993:Bronchodilator Agents; D016166:Free Radical Scavengers; D014665:Vasodilator Agents; D009569:Nitric Oxide